Gefitinib hydrochloride is an EGFR inhibitor, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR.
More Information Supplier PageGAP-134 Hydrochloride, a small modified dipeptide, has been identified as a potent and selective second generation gap junction modifier with oral bioavailability.
More Information Supplier PageGAP-134 Hydrochloride, a small modified dipeptide, has been identified as a potent and selective second generation gap junction modifier with oral bioavailability.
More Information Supplier PageGAP-134 Hydrochloride, a small modified dipeptide, has been identified as a potent and selective second generation gap junction modifier with oral bioavailability.
More Information Supplier PageGAP-134 , a small modified dipeptide, has been identified as a potent and selective second generation gap junction modifier with oral bioavailability.
More Information Supplier PageGAP-134 , a small modified dipeptide, has been identified as a potent and selective second generation gap junction modifier with oral bioavailability.
More Information Supplier PageGAP-134 , a small modified dipeptide, has been identified as a potent and selective second generation gap junction modifier with oral bioavailability.
More Information Supplier PageEsomeprazole Magnesium trihydrate is a proton pump inhibitor which reduces acid secretion through inhibition of the H+ / K+ ATPase in gastric parietal cells.
More Information Supplier Page
